Xilio Therapeutics Inc — Quarterly Cash Flow (NASDAQ:XLO) | MetaTrader

Open full chart

Financials

Overview 성명 Statistics Dividends

Quarterly Annual

Total assets 74.66 M71.08 M103.72 M133.81 M133.69 M Total liabilities 53.68 M53.48 M93.02 M126.74 M141.79 M Total equity 20.97 M17.6 M10.7 M7.07 M8.1 M Total liabilities & shareholders' equities 74.66 M71.08 M103.72 M133.81 M133.69 M Total debt ————— Net debt —————

뉴스

Xilio Therapeutics secures $35.8 million from warrant exercises

Xilio 테라퓨틱스, 시리즈 B 워런트 행사로 3580만 달러 조달

Xilio Development Q3 실적 에상치보다 저조, 수익 예상치를 넘어

Xilio Development earnings missed by $0.06, revenue topped estimates

Xilio Therapeutics, Inc. (XLO) Reports Q3 Loss, Misses Revenue Estimates

BioXcel Therapeutics, Inc. (BTAI) Reports Q3 Loss, Misses Revenue Estimates

Xilio Therapeutics, Inc. (XLO) Discusses Phase 2 Vilastobart Combination Data and High Plasma TMB as Predictive Biomarker in MSS mCRC - Slideshow (NASDAQ:XLO) 2025-11-11

Xilio Therapeutics, Inc. (XLO) Discusses Phase 2 Vilastobart Combination Data and High Plasma TMB as Predictive Biomarker in MSS mCRC Transcript

Xilio presents promising data for tumor-activated immunotherapies

Xilio reports 40% response rate in colorectal cancer treatment study

Xilio to present vilastobart phase 2 data at SITC annual meeting

Xilio 테라퓨틱스, 월요일 나스닥 자본 시장으로 이전 상장